The company’s CEO Jakob Lindberg will summarize the financial year 2018 and address questions from investors, analysts and media.
An audiocast to the presentation will be available at:
Time for webcast – 14.00 (CET) on 22 February Dial in number from Sweden: +46856642706
Dial in number from UK: +443333009270
Dial in number US: +18335268382
For more information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 70 853 72 92
This information was submitted for publication at 10.30 CET, 18 February 2018.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen (Ygalo®), a novel peptide conjugated alkylator that selectively targets multiple myeloma belonging to the class of peptide-enhanced compounds. Melflufen is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with melflufen compared with established alternative drugs for patients with multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
More information is available on www.oncopeptides.com.